Serina Therapeutics
SER
31 hedge funds and large institutions have $2.75M invested in Serina Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.36% → 0.36% (-0%)
3% less funds holding
Funds holding: 32 → 31 (-1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
33% less capital invested
Capital invested by funds: $4.09M → $2.75M (-$1.34M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$22.3K |
| 2 |
Millennium Management
New York
|
+$18.8K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$15.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$12.3K |
| 5 |
LPL Financial
San Diego,
California
|
+$10K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$41.5K |
| 2 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$29K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
| 4 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
-$7.05K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$5K |
SER Hedge Fund Activity: Q2 2022 in Review
31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q2 2022, worth a combined $2.75M — down 33% from $4.09M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SER and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Sigma Planning Corp, adding an estimated $22.3K. The largest seller was BlackRock, cutting an estimated $41.5K.
- 31 institutional investors held Serina Therapeutics (SER) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $2.75M of Serina Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
- 4 funds opened new Serina Therapeutics positions in Q2 2022 and 5 closed out, a net change of -1 holder.
- The largest Serina Therapeutics buyer in Q2 2022 was Sigma Planning Corp, an estimated $22.3K added.
- The largest Serina Therapeutics seller in Q2 2022 was BlackRock, an estimated $41.5K sold.
Based on aggregated 13F filings for Q2 2022.